Saxagliptin - Wikipedia, the free encyclopedia
Saxagliptin , previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. [1]
Development of dipeptidyl peptidase-4 inhibitors - Wikipedia, the free ...
That product was named saxagliptin (Onglyza)(Figure 6). [6] In June 2008 AstraZeneca and Bristol-Myers Squibb submitted a new drug application for Onglyza in the United States and a ...
ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination ...
ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control ...
Verisign Customer Parking Page - Security (SSL Certificates ...
VeriSign Digital Brand Management Systems Customer.VeriSign, Inc. operates intelligent infrastructure services that enable and protect billions of interactions every day across the ...
ONGLYZATM (saxagliptin) Demonstrated Significant Improvements Across ...
Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA™ (saxagliptin), an ...
ONGLYZATM (saxagliptin) With Metformin as Initial ...
ONGLYZA TM (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in ...
ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key ...
ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes SAN FRANCISCO--(Business Wire ...
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates ...
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment. - ROME, September 9 /PRNewswire/ -- Results from a 24-week Phase III ...
Significant New Data For Investigational Diabetes Drug Saxagliptin ...
New data presented for the first time at the 44th European Association for the Study of Diabetes (EASD) Annual Meeting have added to the growing body of evidence, which ...
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates ...
AstraZeneca corporate information, one of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many ...
